Current hepatocellular carcinoma systemic pharmacological treatment options

Liver cancer is the sixth common cancer and the second leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for ~90% of cases of liver cancer and is the fourth most common cause of cancer-related death in the world. Up to now, 4 oral multityrosine kinase inhibitors (soraf...

Full description

Bibliographic Details

Published in:	World Cancer Research Journal
Main Authors:	A. Caturano, M. Monda, R. Galiero, E. Vetrano, C. Giorgione, A. Mormone, M. Rinaldi, R. Marfella, F. Sasso, L. Rinaldi
Format:	Article
Language:	English
Published:	Verduci Editore 2023-05-01
Subjects:	hepatocellular carcinoma systemic pharmacological treatment sorafenib lenvatinib regorafenib cabozantinib ramucirumab atezolizumab plus bevacizumab ipilimumab plus nivolumab nivolumab pembrolizumab tremelimumab plus durvalumab
Online Access:	https://www.wcrj.net/wp-content/uploads/sites/5/2023/05/e2570.pdf